The combination of accelerating revenue growth, margin expansion, and achieving operating profitability suggests strong execution. The raised guidance indicates confidence in sustained momentum. Traders should monitor whether the company can maintain these growth rates and margin improvements in future quarters.
Price Chart
Executive Summary
BillionToOne reported strong fourth quarter and full year 2025 results with revenue up 113% YoY in Q4 and 100% for the full year, driven by significant growth in both prenatal and oncology testing. The company raised its 2026 revenue guidance to $430M-$445M (41%-46% growth) and expects positive operating income for the year. The filing also announced the adoption of an annual incentive plan for employees.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $96.1M, up 113% YoY
- Full year 2025 revenue: $305.1M, up 100% YoY
- Q4 2025 operating income: $10.3M vs. $11.7M loss in Q4 2024
- Full year 2025 operating income: $16.0M vs. $47.1M loss in 2024
- 2026 revenue guidance raised to $430M-$445M (41%-46% growth)
- Company expects positive GAAP operating income for full year 2026
- Gross margin improved to 71% in Q4 2025 from 57% in Q4 2024
Financial Impact
Revenue growth of 100% in 2025 with operating profitability achieved, and guidance raised for 41%-46% revenue growth in 2026
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Prenatal | $277.1M | +90.0% |
| Oncology | $25.0M | +748.0% |
Risk Factors
- Forward-looking statements about 2026 performance are subject to risks and uncertainties
- Company is still in early stages with limited operating history
- Dependence on continued adoption of new diagnostic tests
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002070849-26-000013 |
| Document: blln-20260304.htm | 0002070849-26-000013 |
| Document: 0002070849-26-000013-index-headers.html | 0002070849-26-000013 |
| Document: 0002070849-26-000013-index.html | 0002070849-26-000013 |
| Document: 0002070849-26-000013.txt | 0002070849-26-000013 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | Insider Cluster | $105.76 | awaiting T+60 | — | $107.77 (−1.90%) |
Sep 28, 2026 28d ago | Insider Cluster | $118.18 | awaiting T+60 | — | $107.77 (+8.81%) |
Sep 23, 2026 4w ago | Insider Cluster | $124.90 | awaiting T+60 | — | $107.77 (+13.71%) |
Sep 22, 2026 4w ago | Institutional Cluster | $116.07 | awaiting T+60 | — | $107.77 (−7.15%) |
Sep 21, 2026 5w ago | Insider Cluster | $116.07 | awaiting T+60 | — | $107.77 (+7.15%) |
Sep 16, 2026 5w ago | Insider Cluster | $110.67 | awaiting T+60 | — | $107.77 (+2.62%) |
Sep 11, 2026 6w ago | Insider Cluster | $100.82 | awaiting T+60 | — | $107.77 (+6.89%) |
Sep 11, 2026 6w ago | Insider Cluster | $100.82 | awaiting T+60 | — | $107.77 (+6.89%) |
Aug 27, 2026 8w ago | Insider Cluster | $93.24 | awaiting T+60 | — | $107.77 (+15.58%) |
Aug 27, 2026 8w ago | Insider Cluster | $93.24 | awaiting T+60 | — | $107.77 (+15.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers